Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/Emtricitabine/Tenofovir Alafenamide vs Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment‑Naive HIV‑1 and Hepatitis B Co‑Infected Adults
jRCT2080224956Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 and Chronic Hepatitis B (CHB) comparing Biktarvy single-tablet regimen with Dolutegravir + emtricitabine/tenofovir disoproxil fumarate (2 arms). Started Nov 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidedolutegraviremtricitabine + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080224956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224956.